133 related articles for article (PubMed ID: 38350087)
1. Exploring Theranostic Avenues in Adrenocortical Carcinoma Using Chemokine Receptor and Prostate-Specific Membrane Antigen-Directed PET/CT.
Hahner S; Higuchi T; Serfling SE; Samnick S; Fuss CT; Heinze B; Buck AK; Schirbel A; Fassnacht M; Werner RA
Clin Nucl Med; 2024 Apr; 49(4):369-370. PubMed ID: 38350087
[TBL] [Abstract][Full Text] [Related]
2. Investigating the Chemokine Receptor 4 as Potential Theranostic Target in Adrenocortical Cancer Patients.
Bluemel C; Hahner S; Heinze B; Fassnacht M; Kroiss M; Bley TA; Wester HJ; Kropf S; Lapa C; Schirbel A; Buck AK; Herrmann K
Clin Nucl Med; 2017 Jan; 42(1):e29-e34. PubMed ID: 27819856
[TBL] [Abstract][Full Text] [Related]
3. More advantages in detecting bone and soft tissue metastases from prostate cancer using
Pianou NK; Stavrou PZ; Vlontzou E; Rondogianni P; Exarhos DN; Datseris IE
Hell J Nucl Med; 2019; 22(1):6-9. PubMed ID: 30843003
[TBL] [Abstract][Full Text] [Related]
4. Visualization of Tumor Heterogeneity in Advanced Medullary Thyroid Carcinoma by Dual-Tracer Molecular Imaging: Revealing the Theranostic Potential of SSTR- and PSMA-Directed Endoradiotherapy.
Hasenauer N; Higuchi T; Deschler-Baier B; Hartrampf PE; Pomper MG; Rowe SP; Fassnacht M; Buck AK; Werner RA
Clin Nucl Med; 2022 Jul; 47(7):651-652. PubMed ID: 35085172
[TBL] [Abstract][Full Text] [Related]
5. Theranostics for Advanced Prostate Cancer: Current Indications and Future Developments.
Farolfi A; Fendler W; Iravani A; Haberkorn U; Hicks R; Herrmann K; Walz J; Fanti S
Eur Urol Oncol; 2019 Mar; 2(2):152-162. PubMed ID: 31017091
[TBL] [Abstract][Full Text] [Related]
6. Prostate-Specific Membrane Antigen Expression in Adrenocortical Carcinoma on 68Ga-Prostate-Specific Membrane Antigen PET/CT.
Arora S; Damle NA; Aggarwal S; Passah A; Behera A; Arora G; Bal C; Tripathi M
Clin Nucl Med; 2018 Jun; 43(6):449-451. PubMed ID: 29578871
[TBL] [Abstract][Full Text] [Related]
7. Dual-Tracer PET-Computed Tomography Imaging for Precision Radio-Molecular Theranostics of Prostate Cancer: A Futuristic Perspective.
Adnan A; Basu S
PET Clin; 2022 Oct; 17(4):641-652. PubMed ID: 36153234
[TBL] [Abstract][Full Text] [Related]
8. Imaging Aldosterone-Producing Adrenocortical Carcinoma With 68 Ga-Pentixafor PET/CT.
Shu Q; Deng M; Chen Y; Liu N; Cai L
Clin Nucl Med; 2022 Aug; 47(8):e572-e573. PubMed ID: 35426842
[TBL] [Abstract][Full Text] [Related]
9. Prostate-Specific Membrane Antigen Is a Potential Antiangiogenic Target in Adrenocortical Carcinoma.
Crowley MJ; Scognamiglio T; Liu YF; Kleiman DA; Beninato T; Aronova A; Liu H; Jhanwar YS; Molina A; Tagawa ST; Bander NH; Zarnegar R; Elemento O; Fahey TJ
J Clin Endocrinol Metab; 2016 Mar; 101(3):981-7. PubMed ID: 26771706
[TBL] [Abstract][Full Text] [Related]
10. A Prospective Comparison of
Anttinen M; Ettala O; Malaspina S; Jambor I; Sandell M; Kajander S; Rinta-Kiikka I; Schildt J; Saukko E; Rautio P; Timonen KL; Matikainen T; Noponen T; Saunavaara J; Löyttyniemi E; Taimen P; Kemppainen J; Dean PB; Blanco Sequeiros R; Aronen HJ; Seppänen M; Boström PJ
Eur Urol Oncol; 2021 Aug; 4(4):635-644. PubMed ID: 32675047
[TBL] [Abstract][Full Text] [Related]
11. 68Ga-Prostate-Specific Membrane Antigen PET/CT in Sinonasal Glomangiopericytoma-Exploring Theranostic Avenues!
Sakthivel P; Kumar A; Arunraj ST; Thakur K; Jaiswal AS; Singh CA; Kumar R
Clin Nucl Med; 2021 Apr; 46(4):340-341. PubMed ID: 33323738
[TBL] [Abstract][Full Text] [Related]
12. Impact of the Chemokine Receptors CXCR4 and CXCR7 on Clinical Outcome in Adrenocortical Carcinoma.
Chifu I; Heinze B; Fuss CT; Lang K; Kroiss M; Kircher S; Ronchi CL; Altieri B; Schirbel A; Fassnacht M; Hahner S
Front Endocrinol (Lausanne); 2020; 11():597878. PubMed ID: 33281749
[TBL] [Abstract][Full Text] [Related]
13. Molecular Imaging in the Management of Adrenocortical Cancer: A Systematic Review.
Wong KK; Miller BS; Viglianti BL; Dwamena BA; Gauger PG; Cook GJ; Colletti PM; Rubello D; Gross MD
Clin Nucl Med; 2016 Aug; 41(8):e368-82. PubMed ID: 26825212
[TBL] [Abstract][Full Text] [Related]
14. 68Ga-Prostate-Specific Membrane Antigen-Avid Malignant Pleural Effusion in a Patient With Metastatic Adenoid Cystic Carcinoma and Concordance With 18F-FDG PET/CT.
Uijen MJM; Weijers JAM; Driessen CML; van Herpen CML; Nagarajah J
Clin Nucl Med; 2022 Feb; 47(2):140-141. PubMed ID: 35006109
[TBL] [Abstract][Full Text] [Related]
15.
van Boxtel W; Lütje S; van Engen-van Grunsven ICH; Verhaegh GW; Schalken JA; Jonker MA; Nagarajah J; Gotthardt M; van Herpen CML
Theranostics; 2020; 10(5):2273-2283. PubMed ID: 32089741
[No Abstract] [Full Text] [Related]
16. Role of FDG PET/CT in Management of Patients with Prostate Cancer.
Sutherland DEK; Azad AA; Murphy DG; Eapen RS; Kostos L; Hofman MS
Semin Nucl Med; 2024 Jan; 54(1):4-13. PubMed ID: 37400321
[TBL] [Abstract][Full Text] [Related]
17.
von Eyben FE; Picchio M; von Eyben R; Rhee H; Bauman G
Eur Urol Focus; 2018 Sep; 4(5):686-693. PubMed ID: 28753806
[TBL] [Abstract][Full Text] [Related]
18. Is Prostate-specific Membrane Antigen Positron Emission Tomography/Computed Tomography Imaging Cost-effective in Prostate Cancer: An Analysis Informed by the proPSMA Trial.
de Feria Cardet RE; Hofman MS; Segard T; Yim J; Williams S; Francis RJ; Frydenberg M; Lawrentschuk N; Murphy DG; De Abreu Lourenco R
Eur Urol; 2021 Mar; 79(3):413-418. PubMed ID: 33341285
[TBL] [Abstract][Full Text] [Related]
19. 68Ga-DOTAGA-IAC PET/CT for Imaging Metastatic and Recurrent Adrenocortical Carcinoma: A Case Series.
Pandey S; Walia R; Kumar R; Chopra S; Rana N; Chatterjee D; Satz S; Mittal BR; Shukla J
Clin Nucl Med; 2023 Feb; 48(2):e95-e98. PubMed ID: 36607383
[TBL] [Abstract][Full Text] [Related]
20. [PSMA-based theranostics for prostate cancer : From imaging to treatment].
Ilhan H; la Fougère C; Krause BJ
Urologe A; 2020 May; 59(5):617-625. PubMed ID: 32377764
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
